<DOC>
	<DOCNO>NCT00720265</DOCNO>
	<brief_summary>To prove non-inferiority MR4 Prograf evaluate efficacy safety Prograf MR4 new kidney transplant recipient</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Prograf MR4 Kidney Transplantation Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patient must receive first oral dose randomize study drug 2days ( min 1day ) prior transplant procedure Female patient child bear potential must negative urine serum pregnancy test within 7 day prior enrollment Patient previously receive organ transplant kidney Patient receive Kidney transplant nonheart beat donor cadaveric donor Patients receive ABO incompatible donor kidney Recipient donor know seropositive human immunodeficiency virus ( HIV ) Patient current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully Patient significant liver , disease , define past 28 day continuously elevate AST ( SGOT ) and/or ALT ( SGPT ) level great 3 time upper value normal range investigational site Patient uncontrolled concomitant infection ( include Hepatitis B , Hepatitis C ) unstable medical condition could interfere study objective Patient currently take take immunosuppressive agent 30 day prior transplant ( except two day prior transplant ) Patient know hypersensitivity tacrolimus Patient pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Organ Transplantation</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>FK506MR</keyword>
</DOC>